Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.27 USD
Change Today +0.0004 / 0.15%
Volume 571.8K
LPTN On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

4025 Sorrento Valley Boulevard

San Diego, CA 92121

United States

Phone: 858-678-0800

Fax: 858-678-0900

Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies. The company has two product candidates that are currently in clinical development, and one in pre-clinical evaluation. iSONEP iSONEP is the ocular formulation of sonepcizumab, a humanized monoclonal antibody (mAb) against sphingosine-1-phosphate (S1P). Sphingomab is the original mouse version of this monoclonal antibody. iSONEP is administered by intravitreal injection, and has demonstrated multiple mechanisms of action in ocular models of disease, including anti-angiogenesis, anti-inflammatory, anti-fibrotic and anti-vascular permeability. ASONEP ASONEP is the systemic formulation of sonepcizumab. In 2010, the company completed a Phase 1 clinical trial in which ASONEP was evaluated in very late-stage cancer patients. In that trial, ASONEP was well tolerated at all dose-levels ranging from 1 mg/kg to 24 mg/kg., other than minor infusion-related reactions observed at the highest dose. In collaboration with Beth Israel Deaconess Medical Center, the company has demonstrated efficacy of ASONEP in preclinical models of a form of human kidney cancer called renal cell carcinoma. Lpathomab Lpathomab, a pre-clinical product candidate, is a mAb against lysophosphatidic acid (LPA), a key bioactive lipid that has been recognized as a significant promoter of cancer-cell growth and metastasis in a range of tumor types. The company has selected the clinical candidate mAb from among three humanized mAbs that inhibit LPA. These mAbs were tested against each other in various models of human disease to determine which mAb would be most likely to succeed in clinical trials. Intellectual-Property The company’s intellectual-property position in the bioactive-lipid area includes 82 issued patents, including 53 foreign patents, and 114 patent applications, including 88 foreign patent applications. Government Regulation The company is required to submit the results of its preclinical tests, together with manufacturing information and analytical data, to the U.S. Food and Drug Administration as part of an Investigational New Drug Application, which must become effective before the company may begin human clinical trials.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPTN:US $0.27 USD +0.0004

LPTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LPTN.
View Industry Companies

Industry Analysis


Industry Average

Valuation LPTN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.3x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LPATH INC-CLASS A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at